NewsEvents

Your Yourlocation: Home > Pharmacy guardianship of tiotropium bromide(136310-93-5) treatment

Screening of patients, clear cause of AUR patients have many years of chronic obstructive pulmonary disease, pulmonary heart disease history, several times in our hospital respiratory hospitalization, the admission respiratory failure, drowsiness, blood gas analysis prompted significant carbon dioxide retention, hospitalization history, had invasive mechanical ventilation, consciousness conscious sleepiness, admitted to intensive care unit, if necessary, consider mechanical ventilation, continuous nasal catheter after admission oxygen, supplemented by anti-infective, inhalation of diastolic airway, expectorant, expansion and other symptomatic treatment, encourage patients to exercise respiratory function, the spirit of patients turn for the better check blood gas than the previous improvement, resting state is still chest tightness, shortness of breath performance, taking into account patients with long-term use of formoterol (18μg, inhalation, qd), January 12 when the rounds of patients with early air improved significantly, the prosecution palpitation, difficulty falling asleep, clinical pharmacists to ask history, patients with dry mouth, clinical pharmacists and attending physician communication, may be related to medication, suspected drug tiotropium bromide(136310-93-5), the patient reviewed the ECG, the results showed that pulmonary heart disease, consider tiotropium bromide(136310-93-5) inhalation medication systemic adverse reactions, dry mouth symptoms with the continued treatment will generally disappear, and patients with symptoms improved significantly, the attending physician recommendations can continue to use, clinical pharmacists agree and strengthen the patient's pharmacy care, January 13 morning check room, patients still have dry mouth discomfort, at 13:00 on January 13 patients with acute urinary retention, and finally give relief of symptoms after indwelling catheter, clinical pharmacists based on patient history and medication, access to relevant information: inhaled anticholinergic drugs are widely used in the treatment of COPD, but Canada, Europe And the US clinical guidelines for these drugs may have adverse effects on the prostate suggest less, the results of clinical research is not uniform. A Canadian-based hospital conducted a community-based case-control study.

The results show that the use of inhaled anticholinergic drugs (including short-acting ipratropium bromide and long-acting tiotropium) in men over the age of 66 is associated with a 40% greater risk of developing AUR than men who do not. Clinical pharmacists consider patients with AUR "likely" and tiotropium bromide(136310-93-5) related to the proposed discontinuation, the attending physician said to communicate with the higher physician, to further discuss the adjustment of treatment programs, while improving the prostate ultrasound.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved